Ann: Appendix 4C - quarterly, page-6

Yep, joining the negative sentiment today, because this is a missed opportunity to give us something - so it really does seem like groundhog day.
12 months ago I was expecting POP approvals - no reason given for delay.
No idea of 'new strategy'.
No new hospital trials for the burette; way too slow.  It's important to note shareholders weren't given the real explanation for the stall lasting several years, or why they didn't take action on the issue.  So they're capable of keeping us in the dark if there's any major issues with Pericoach, despite that being illegal.
What is the R & D for, & why?  Is it just to pay certain people and continue to get a refund?  Why not shut down until a deal is done?
Are they doing anything to try and demonstrate sales success - a key issue in negotiations; if not - why not?
Credibility is finite.  I'm not yet concerned with the time it's taking to get a deal, but as we get closer to the need for more dilution ...